Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.64 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | HSPB1 | P04792 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 3/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | MMP13 | P45452 | 4/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | DRD1 | P21728 | 1/20 | 0.42 |
| ▸ | DRD5 | P21918 | 1/20 | 0.42 |
| ▸ | DRD3 | P35462 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15384990 | 0.89 | MEN1 (0.59) | MEN1KMT2AKDM4EL3MBTL1ALDH1A1 | |
| SCHEMBL8737052 | 0.88 | KDM4E (0.66) | MEN1KMT2AKDM4EL3MBTL1ALDH1A1 | |
| SCHEMBL4598049 | 0.83 | KDM4E (0.56) | MEN1KMT2AKDM4EL3MBTL1ALDH1A1 | |
| SCHEMBL21686324 | 0.82 | KDM4E (0.47) | MEN1KMT2AKDM4EL3MBTL1ALDH1A1 | |
| SCHEMBL4598208 | 0.81 | KDM4E (0.54) | MEN1KMT2AKDM4EL3MBTL1ALDH1A1 | |
| SCHEMBL12102113 | 0.81 | KDM4E (0.54) | MEN1KMT2AKDM4EL3MBTL1ALDH1A1 | |
| SCHEMBL17427864 | 0.81 | KDM4E (0.54) | MEN1KMT2AKDM4EL3MBTL1ALDH1A1 | |
| SCHEMBL4597506 | 0.81 | KDM4E (0.54) | MEN1KMT2AKDM4EALDH1A1RAB9A | |
| SCHEMBL8306130 | 0.81 | KDM4E (0.53) | MEN1KMT2AKDM4EL3MBTL1ALDH1A1 | |
| SCHEMBL8737477 | 0.81 | LIPE (0.56) | MEN1KMT2AKDM4ERAB9APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3293184-B1 | PYRIMIDINE CARBOXAMIDES AS SODIUM CHANNEL BLOCKERS | PURDUE PHARMA LP (US) | 2020-12-16 | — | — | EP | disclosed |
| US-10774050-B2 | Pyrimidines as sodium channel blockers | PURDUE PHARMA, L.P. (US) | 2020-09-15 | — | — | US | disclosed |
| US-10196364-B2 | Pyrimidine carboxamides as sodium channel blockers | PURDUE PHARMA L.P. (US) | 2019-02-05 | — | — | US | disclosed |
| US-20190002412-A1 | PYRIMIDINES AS SODIUM CHANNEL BLOCKERS | PURDUE PHARMA L.P. | 2019-01-03 | — | — | US | disclosed |
| EP-2964639-B1 | PYRIMIDINE CARBOXAMIDES AS SODIUM CHANNEL BLOCKERS | PURDUE PHARMA LP (US) | 2018-05-02 | — | — | EP | disclosed |
| WO-2018075858-A1 | METHODS OF USING INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS | SAMUMED, LLC (US) | 2018-04-26 | — | — | WO | disclosed |
| EP-2871180-B1 | 2-AMINONICOTINIC ACID ESTER DERIVATIVE AND BACTERICIDE CONTAINING SAME AS ACTIVE INGREDIENT | AGRO KANESHO CO LTD (JP) | 2018-03-21 | — | — | EP | disclosed |
| EP-3293184-A1 | PYRIMIDINE CARBOXAMIDES AS SODIUM CHANNEL BLOCKERS | Purdue Pharma L.P. (US) | 2018-03-14 | — | — | EP | disclosed |
| US-20170298027-A1 | PYRIMIDINES AS SODIUM CHANNEL BLOCKERS | PURDUE PHARMA L.P. (US) | 2017-10-19 | — | — | US | disclosed |
| US-20170210713-A1 | PYRIMIDINE CARBOXAMIDES AS SODIUM CHANNEL BLOCKERS | PURDUE PHARMA L.P. | 2017-07-27 | — | — | US | disclosed |
| US-20100016337-A1 | HETEROARYL-SUBSTITUTED CARBOXAMIDES AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (FR) | 2010-01-21 | — | — | US | disclosed |
| US-7629341-B2 | e.g. N1-hydroxy-N2-[(4-phenoxyphenyl)sulfonyl]-D-argininamide; metallopeptidase inhibitor; antiinflammation, anticarcinogenic, antidiabetic agent; angiogenesis inhibitor; atherosclerosis, stroke, ulcer, infertility, scleroderma, endometriosis, mesothelioma | SYMPHONY EVOLUTION, INC. (US) | 2009-12-08 | — | — | US | disclosed |
| US-20090220514-A1 | ADAM10 and its Uses Related to Infection | VANDERBILT UNIVERSITY | 2009-09-03 | — | — | US | disclosed |
| US-20080269265-A1 | Inhibition Of Raf Kinase Using Symmetrical And Unsymmetrical Substituted Diphenyl Ureas | MILLER SCOTT | 2008-10-30 | — | — | US | disclosed |
| US-20080269265-A1 | Inhibition Of Raf Kinase Using Symmetrical And Unsymmetrical Substituted Diphenyl Ureas | MILLER SCOTT | 2008-10-30 | — | — | US | disclosed |
| WO-2008077507-A1 | HETEROARYL-SUBSTITUTED CARBOXAMIDES AND USE THEREOF FOR THE STIMULATION OF THE EXPRESSION OF NO SYNTHASE | SANOFI-AVENTIS (FR) | 2008-07-03 | — | — | WO | disclosed |
| EP-1939181-A1 | Heteroaryl-substituted carboxamides and use thereof for the stimulation of the expression of NO synthase | sanofi-aventis (FR) | 2008-07-02 | — | — | EP | disclosed |
| US-20080027050-A1 | Heterocyclic Amide Compound and Use Thereof as an Mmp-13 Inhibitor(Amended Ex Officio) | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-01-31 | — | — | US | disclosed |
| US-20080027050-A1 | Heterocyclic Amide Compound and Use Thereof as an Mmp-13 Inhibitor(Amended Ex Officio) | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-01-31 | — | — | US | disclosed |
| WO-2005105760-A1 | HETEROCYCLIC AMIDE COMPOUND AND USE THEREOF AS AN MMP-13 INHIBITOR | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10196364-B2 | Pyrimidine carboxamides as sodium channel blockers | CACNA1A, TRPV1, TRPA1 | MEN1 3827/4885KMT2A 2205/4885KDM4E 2252/4885 |
| US-20080027050-A1 | Heterocyclic Amide Compound and Use Thereof as an Mmp-13 Inhibitor(Amended Ex Officio) | MMP13, HDAC11, HDAC1 | MEN1 3549/4885KMT2A 634/4885KDM4E 1156/4885 |
| US-20170298027-A1 | PYRIMIDINES AS SODIUM CHANNEL BLOCKERS | P2RX3, CACNA1A, P2RX4 | MEN1 4132/4885KMT2A 3494/4885KDM4E 3092/4885 |
| US-20190002412-A1 | PYRIMIDINES AS SODIUM CHANNEL BLOCKERS | P2RX3, CACNA1A, P2RX4 | MEN1 4132/4885KMT2A 3494/4885KDM4E 3092/4885 |
| US-20090220514-A1 | ADAM10 and its Uses Related to Infection | ADAM10, ADAM12, ADAM17 | MEN1 1083/4885KMT2A 4376/4885KDM4E 4160/4885 |
| US-20170210713-A1 | PYRIMIDINE CARBOXAMIDES AS SODIUM CHANNEL BLOCKERS | CACNA1A, TRPV1, TRPA1 | MEN1 3827/4885KMT2A 2205/4885KDM4E 2252/4885 |
| US-10774050-B2 | Pyrimidines as sodium channel blockers | P2RX3, CACNA1A, P2RX4 | MEN1 4132/4885KMT2A 3494/4885KDM4E 3092/4885 |
| US-20100016337-A1 | HETEROARYL-SUBSTITUTED CARBOXAMIDES AND THEIR USE AS PHARMACEUTICALS | TBXAS1, PTGIS, NOS2 | MEN1 3768/4885KMT2A 1573/4885KDM4E 908/4885 |
| US-20080269265-A1 | Inhibition Of Raf Kinase Using Symmetrical And Unsymmetrical Substituted Diphenyl Ureas | BRAF, RAF1, MAP2K2 | MEN1 3509/4885KMT2A 1888/4885KDM4E 1268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.